Intron-A [interferon alpha-2b]/Aldara [imiquimod] combination therapy for BCC [basal cell carcinoma] excluding the face and scalp

Trial Profile

Intron-A [interferon alpha-2b]/Aldara [imiquimod] combination therapy for BCC [basal cell carcinoma] excluding the face and scalp

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jan 2013

At a glance

  • Drugs Imiquimod (Primary) ; Interferon alpha-2b (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2011 Planned end date changed from May 2011 to Sep 2011 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned number of patients changed from 40 to 49 as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Dec 2010 to 1 May 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top